​

CorMedix (CRMD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CRMD Stock Forecast

CorMedix (CRMD) stock forecast, based on 6 Wall Street analysts, predicts a 12-month average price target of $19.50, with a high of $22.00 and a low of $17.00. This represents a 75.04% increase from the last price of $11.14.

- $5 $10 $15 $20 $25 High: $22 Avg: $19.5 Low: $17 Last Closed Price: $11.14

CRMD Stock Rating

CorMedix stock's rating consensus is Buy, based on 6 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 6 0 6 Strong Sell Sell Hold Buy Strong Buy

CRMD Price Target Upside V Benchmarks

TypeNameUpside
StockCorMedix75.04%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts122
Avg Price Target$22.00$19.50$19.50
Last Closing Price$11.14$11.14$11.14
Upside/Downside97.49%75.04%75.04%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25421--7
Sep, 2542---6
Aug, 25421--7
Jul, 25421--7
Jun, 2533---6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 21, 2025Gregory RenzaRBC Capital$22.00$12.1680.92%97.49%
Aug 08, 2025Brandon FolkesH.C. Wainwright$17.00$10.3364.57%52.60%
Mar 13, 2024Gregory RenzaRBC Capital$9.00$3.90130.77%-19.21%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 21, 2025RBC CapitalOutperformOutperformhold
Aug 08, 2025H.C. WainwrightBuyBuyhold
Dec 19, 2024RBC CapitalOutperformOutperformhold
Aug 26, 2024Rodman & RenshawBuyinitialise
Aug 10, 2023RBC CapitalOutperforminitialise
Apr 25, 2022Zacks Investment ResearchSelldowngrade

Financial Forecast

EPS Forecast

$-350 $-270 $-190 $-110 $-30 $50 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.77$-0.75$-0.74$-0.91$-304.56----
Avg Forecast$-0.82$-0.80$-0.73$-0.85$-0.41$0.50$0.98$1.81$2.68
High Forecast$-0.70$-0.68$-0.72$-0.78$-0.38$0.59$1.33$2.56$3.18
Low Forecast$-0.94$-0.91$-0.75$-1.01$-0.49$0.46$0.74$0.99$2.46
Surprise %-6.10%-6.25%1.37%7.06%74182.93%----

Revenue Forecast

$-5B $5B $15B $25B $35B $45B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$239.23K$190.94K$65.41K-$43.47B----
Avg Forecast$210.60K$124.33K$26.23K$-333.33K$39.55M$126.15M$161.46M$238.61M$330.20M
High Forecast$234.12K$138.22K$26.63K$-312.64K$45.29M$144.46M$162.55M$240.51M$378.14M
Low Forecast$187.44K$110.66K$25.94K$-381.72K$37.09M$118.32M$160.37M$236.71M$309.70M
Surprise %13.59%53.57%149.33%-109816.07%----

Net Income Forecast

$-20B $-15B $-10B $-5B $0 $5B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-22.03M$-28.21M$-29.70M$-46.34M$-17.93B----
Avg Forecast$-41.74M$-40.55M$-37.19M$-46.34M$-22.00M$26.74M$52.56M$90.20M$136.17M
High Forecast$-35.77M$-34.76M$-36.66M$-39.77M$-19.19M$30.15M$67.68M$130.16M$161.86M
Low Forecast$-47.80M$-46.44M$-37.93M$-51.42M$-24.81M$23.32M$37.44M$50.25M$125.18M
Surprise %-47.23%-30.44%-20.14%-81410.49%----

CRMD Forecast FAQ

Is CorMedix stock a buy?

CorMedix stock has a consensus rating of Buy, based on 6 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that CorMedix is a favorable investment for most analysts.

What is CorMedix's price target?

CorMedix's price target, set by 6 Wall Street analysts, averages $19.5 over the next 12 months. The price target range spans from $17 at the low end to $22 at the high end, suggesting a potential 75.04% change from the previous closing price of $11.14.

How does CorMedix stock forecast compare to its benchmarks?

CorMedix's stock forecast shows a 75.04% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for CorMedix over the past three months?

  • October 2025: 57.14% Strong Buy, 28.57% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 66.67% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 57.14% Strong Buy, 28.57% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.

What is CorMedix’s EPS forecast?

CorMedix's average annual EPS forecast for its fiscal year ending in December 2025 is $0.5, marking a -100.16% decrease from the reported $-305 in 2024. Estimates for the following years are $0.98 in 2026, $1.81 in 2027, and $2.68 in 2028.

What is CorMedix’s revenue forecast?

CorMedix's average annual revenue forecast for its fiscal year ending in December 2025 is $126.15M, reflecting a -99.71% decrease from the reported $43.47B in 2024. The forecast for 2026 is $161.46M, followed by $238.61M for 2027, and $330.2M for 2028.

What is CorMedix’s net income forecast?

CorMedix's net income forecast for the fiscal year ending in December 2025 stands at $26.74M, representing a -100.15% decrease from the reported $-17.93B in 2024. Projections indicate $52.56M in 2026, $90.2M in 2027, and $136.17M in 2028.